Abstracts Archive - Page 173 of 2607 - ACR Meeting Abstracts

Abstract Number: 1124 • ACR Convergence 2025
ABCG2 Variants as Genetic Risk Factors for Hyperuricemia and Gout: Focus on Pediatric and Familial Manifestations
Blanka Stiburkova¹, katerina pavelcova², Jana masinova³, Pavel Jesina⁴, Yu Toyoda⁵ and Tappei Takada⁵, ¹Institute of Rheumatology, Praha ¹⁰, Czech Republic, ²Institute of Rheumatology, Praha ², Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Revmatologický ústav, Praha ², Czech Republic, ⁵The University of Tokyo Hospital, Tokyo, Japan
Background/Purpose: Gout, a condition arising from hyperuricemia, is considered as both a metabolic disorder and an autoinflammatory disease. Genetic factors are estimated to contribute approximately…
Abstract Number: 1140 • ACR Convergence 2025
PGG Suppresses MSU Crystal–Triggered Inflammation and Arachidonic Acid Production in PBMCs
Sadiq Umar¹, Poorna Chandra Rao Yalagala², Sugasini Dhavamani² and Sriram Ravindran², ¹University of Illinois at Chicago, Chicago, IL, ²University of Illinois, Chicago, IL
Background/Purpose: Gout is the most prevalent inflammatory arthritis globally, with rising incidence in both developed and developing regions. It is driven by monosodium urate (MSU)…
Abstract Number: 1070 • ACR Convergence 2025
Cervical Cancer and HPV Screening in Women with Lupus vs Healthy Control Group: A Retrospective Study at a Tertiary Referral Center
Mahnoor Javed¹, Deepak Jagannath², Alma Aveytia Camacho³, Alwyn Mathew³, Konrad Harms³, Soudabeh Daliri³ and Myriam Guevara⁴, ¹Houston Methodist, Richmond, TX, ²Houston Methodist Hospital, Sugar Land, TX, ³Houston Methodist, Houston, ⁴Houston Methodist, Houston, TX
Background/Purpose: Women with SLE are at an increased risk of developing cervical cancer, primarily by human papillomavirus (HPV) and immunosuppression. This elevated risk has been…
Abstract Number: 1106 • ACR Convergence 2025
Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan
Ko-Jen Li¹, Ting-Wei Chang², Tso-Ting Lai³, Jui-Hung Kao⁴, TING-YUAN LAN⁵, Tai-Ju Lee⁶, pei-Hsinq lai⁷, Shao-Yu Pai⁸, Chiehyu Shen⁹ and Song-Chou Hsieh¹⁰, ¹National Taiwan University Hospital, Taipei, Taiwan, ²National Taiwan University Hospital Hsinchu Branch, Taichung, Taiwan, ³Naitional Taiwan University Hospital, Taipei, Taiwan (Republic of China), ⁴Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Taipei, Taiwan (Republic of China), ⁵National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ⁶National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), ⁷Taipei City Hospital, Taichung, Taiwan, ⁸National Taiwan University Hospital, Taichung City, Taiwan (Republic of China), ⁹National Taiwan University Hospital, Taipei city, Taiwan, ¹⁰National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: Hydroxychloroquine (HCQ) retinopathy is a progressive, vision-threatening retinal disease. While HCQ is typically discontinued after toxicity is detected, some patients undergo tapering due to…
Abstract Number: 1164 • ACR Convergence 2025
Effect of TNF Inhibitors on the Postprandial Glucose Homeostasis Molecules: Amylin, Gastric Inhibitory Polypeptide, and Pancreatic Polypeptide in Rheumatic Patients
José Carlos García-Hernández¹, Iván Ferraz Amaro², Marta Hernández Díaz², Ana Isabel Rodríguez Vargas¹ and Federico Díaz González¹, ¹Hospital Universitario de Canarias, Santa Cruz De Tenerife, Canarias, Spain, ²Servicio Canario de Salud, La Laguna, Canarias, Spain
Background/Purpose: The effect of systemic TNF inhibition on postprandial glucose homeostasis, a parameter associated with cardiovascular health, remains unclear. This study aims to evaluate the…
Abstract Number: 1153 • ACR Convergence 2025
New Disease Classification in the Block? A 5-year Retrospective Review on Clinical Profiles and Mortality Outcomes of Patients Presenting with Hematoinflammatory Syndromes at a University Center in Florida
Cristine Kuzhuppilly Arcilla¹, Gabriel Kirsch², Michael Cargill² and Gurjit Kaeley³, ¹University of Florida Jacksonville, Jacksonville, FL, ²University of Florida - Jacksonville, Jacksonville, FL, ³UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: The novel diagnosis of VEXAS in 2020 led to the proposed possibility of a new category of hematoinflammatory syndromes linking clinically overlapping hematologic and…
Abstract Number: 1134 • ACR Convergence 2025
Efficacy and Safety of Anakinra for Acute Calcium Pyrophosphate Deposition Disease Flare: A Systematic Review and Meta-Analysis
Pannathorn Nakaphan¹, Somkiat Phutinart², Patavee Pajareya², Priabprat Jansem³, Nattanicha Chaisrimaneepan⁴, Pim Jetanalin⁵ and Noppachai Siranart², ¹Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, ²Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ³Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ⁵Department of Medicine, Division of Rheumatology, University of Illinois College of Medicine, Chicago, IL
Background/Purpose: Calcium Pyrophosphate Deposition Disease (CPPD) is a common inflammatory arthritis among older adults. Comorbidities often limit conventional treatment of acute CPPD flare. Anakinra, an…
Abstract Number: 1081 • ACR Convergence 2025
Insurance, Gender, and COVID-19’s Effects on Health Inequity in Rheumatoid Arthritis: A 12-Year Long Population Assessment
Ramsha Riaz¹, Lifang Zhang², Andrea Berger², Hema Srinivasan², Lisa Schroeder³ and Jonida Cote⁴, ¹Geisinger Medical Center, Danville, PA, ²Geisinger Health System, Danville, PA, ³Geisinger, Danville, PA, ⁴Geisinger Health System, Wilkes-Barre, PA
Background/Purpose: Recognizing health care disparities in Rheumatoid Arthritis is crucial to improving outcomes. This study analyzes factors contributing to RA care inequities.Methods: We examined RA…
Abstract Number: 1170 • ACR Convergence 2025
A20 Haploinsufficiency (HA20): TNFAIP3 Mutation Prevalence In A Clinically Compatible Cohort
María Alonso de Francisco¹, Emiliano González Vioque², Pablo Navarro Palomo³, Maria Machattou⁴, Carlota Navarro Joven⁴, Laura Ramos Ortiz de Zarate⁴, Alejandro Martínez⁵, Adriana Martín Bescós⁴, Paula Mazo⁴, María Concepción Sánchez Fernández⁴, Andrea Liso Andrino⁴, Maria Carmen Barbadillo Mateos⁶, JESUS SANZ SANZ⁷, Hildegarda Godoy Tundidor⁴, Jose Campos⁸, Monica Fernandez Castro⁹, Blanca García Magallón⁴, Olga Rusinovich¹⁰, Laura Nuño¹¹, Jose Luis Andreu¹² and Carolina Merino¹³, ¹H. U. Puerta de Hierro Majadahonda, Tres Cantos, Spain, ²Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ³Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain, ⁴Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁵Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Afghanistan, ⁶Public, Madrid, Spain, ⁷SERMAS, Madrid, Spain, ⁸Hospital Universitario Principe de Asturias, Madrid, Spain, ⁹PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ¹⁰Puerta de Hierro Majadahonda University Hospital, Boadilla del Monte, Spain, ¹¹Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹²Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹³Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain
Background/Purpose: Haploinsufficiency of A20 (HA20) is a disease at the crossroads between autoinflammation and autoimmunity, caused by heterozygous mutations in TNFAIP3, which encodes the A20…
Abstract Number: 1166 • ACR Convergence 2025
Biomarkers Associated with Left Atrial Structure and Function in Individuals with Psoriasis
Julie Borchsenius¹, Maria Dons², Morten Sengeløv³, Flemming Olsen⁴, Caroline Espersen⁴, Kristoffer Skaarup³, Mats Lassen⁴, Niklas Johansen⁴, Filip Davidovski³, Manan Pareek⁴, Brittany Weber⁵, Claus Zachariae⁶, Lone Skov⁶ and Tor Biering-Sørensen³, ¹CTCPR / Center for translational cardiology and pragmatic research trials, Charlottenlund, Denmark, ²Copenhagen University Hospital Gentofte, Copenhagen, Hovedstaden, Denmark, ³Center for Translational Cardiology and Pragmatic Randomized Trials, Dep. of Cardiology, Copenhagen University Hospital - Gentofte, Copenhagen, Hovedstaden, Denmark, ⁴CTCPR / Center for translational cardiology and pragmatic research trials, Copenhagen, Denmark, ⁵Brigham and Women's Hospital, DEDHAM, MA, ⁶Dep. of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark
Background/Purpose: Individuals with psoriasis are at increased risk of developing heart disease. Echocardiographic parameters of impaired left atrial (LA) strain (Peak atrial contraction and longitudinal…
Abstract Number: 1116 • ACR Convergence 2025
Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis
Sarah Sun¹, Cathryn Lee² and Pankti Reid³, ¹University of Chicago, Chicago, IL, ²University of Chicago, Chicago, ³University of Chicago Medical Center, Chicago, IL
Background/Purpose: Immune checkpoint inhibitors (ICIs) used for cancer therapy can have varied toxicities among which pneumonitis (ICI-pneumonitis) is a rare (< 5%) but often fatal…
Abstract Number: 1159 • ACR Convergence 2025
IL-18 Correlates with Pouchot Score and Inflammatory Biomarkers in Adult-Onset Still’s Disease: Insights From a Repeated Measures Study
Hadeel Abdul-Rehman¹, Karen Gambina² and Bella Mehta³, ¹Hospital for Special Surgery, New York, NY, ²Columbia University Medical Center, Islip, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Adult-Onset Still’s Disease (AOSD) is a rare systemic inflammatory disease. Interleukin-18 (IL-18) levels are significantly elevated in AOSD patients¹ and may be a promising…
Abstract Number: 1089 • ACR Convergence 2025
Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry
Alice Tison¹, Deanna Jannat-Khah², Laura Cappelli³ and Anne R. Bass², ¹LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ²Hospital For Special Surgery, New York, NY, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Inflammatory arthritis (IA)- and polymyalgia rheumatica (PMR)-like syndromes occur in about 6% of patients receiving an immune checkpoint inhibitor (ICI) and can worsen quality…
Abstract Number: 1178 • ACR Convergence 2025
An International modified Delphi Study on the evolving role of Janus kinase inhibitors (JAKi) in rheumatic and musculoskeletal diseases (RMDs)
Anna Barkaway¹, Philip J. Mease², Zoe Rutter-Locher³, Robert Moots⁴, Mwidimi Ndosi⁵ and Michael McLean⁶, ¹Pfizer UK, Tadworth, United Kingdom, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Guys and St Thomas NHS trust, London, United Kingdom, ⁴Liverpool University Hospitals, Liverpool, United Kingdom, ⁵University of the West of England, Bristol, Filton, United Kingdom, ⁶Pfizer, Glasgow, United Kingdom
Background/Purpose: The development of advanced therapies such as JAK inhibitors (JAKi) has expanded treatment options available for patients with rheumatic and musculoskeletal diseases (RMDs). Case…
Abstract Number: 1176 • ACR Convergence 2025
VISIBLE Post-Inflammatory Pigmentation Journeys: Exploring the Impact of Pigmentation
Tarek Dawamne¹, Olivia Choi, MD, PhD, FAAD², Alison Tran³, Jacob Beer⁴, Katelyn Rowland², Theodore Alkousakis², Oyediran Adelakun², Elizabeth Skobelev², Sancharitha Ramji², Tony Ma⁵, Daphne Chan² and Jenna Lester⁶, ¹Texas A&M School of Engineering Medicine, Houston, TX, USA, Houston, TX, ²Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ³Lake Granbury Medical Center, Department of Dermatology, Dallas, TX, USA, Dallas, TX, ⁴Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami, FL, USA, Miami, FL, ⁵Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁶University of California, San Francisco, CA, USA, San Francisco, CA
Background/Purpose: Post-inflammatory pigment alteration (PIPA) following resolution of psoriasis plaques is an important, neglected problem that disproportionately impacts people of color.1-3 VISIBLE, an ongoing Phase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].